S&P 500   4,564.41 (-0.12%)
DOW   36,107.39 (-0.27%)
QQQ   386.78 (+0.12%)
AAPL   193.04 (+1.91%)
MSFT   371.97 (+0.77%)
META   318.28 (-0.54%)
GOOGL   130.87 (+1.24%)
AMZN   146.86 (+1.39%)
TSLA   238.40 (+1.20%)
NVDA   463.52 (+1.85%)
NIO   7.46 (+1.91%)
BABA   72.63 (-0.55%)
AMD   118.21 (-0.30%)
T   17.22 (+3.36%)
F   10.61 (-0.84%)
MU   73.70 (-0.79%)
CGC   0.66 (-12.31%)
GE   120.15 (-1.14%)
DIS   90.65 (-1.48%)
AMC   7.04 (-6.01%)
PFE   29.17 (-0.38%)
PYPL   57.65 (-3.68%)
XOM   100.63 (-1.76%)
S&P 500   4,564.41 (-0.12%)
DOW   36,107.39 (-0.27%)
QQQ   386.78 (+0.12%)
AAPL   193.04 (+1.91%)
MSFT   371.97 (+0.77%)
META   318.28 (-0.54%)
GOOGL   130.87 (+1.24%)
AMZN   146.86 (+1.39%)
TSLA   238.40 (+1.20%)
NVDA   463.52 (+1.85%)
NIO   7.46 (+1.91%)
BABA   72.63 (-0.55%)
AMD   118.21 (-0.30%)
T   17.22 (+3.36%)
F   10.61 (-0.84%)
MU   73.70 (-0.79%)
CGC   0.66 (-12.31%)
GE   120.15 (-1.14%)
DIS   90.65 (-1.48%)
AMC   7.04 (-6.01%)
PFE   29.17 (-0.38%)
PYPL   57.65 (-3.68%)
XOM   100.63 (-1.76%)
S&P 500   4,564.41 (-0.12%)
DOW   36,107.39 (-0.27%)
QQQ   386.78 (+0.12%)
AAPL   193.04 (+1.91%)
MSFT   371.97 (+0.77%)
META   318.28 (-0.54%)
GOOGL   130.87 (+1.24%)
AMZN   146.86 (+1.39%)
TSLA   238.40 (+1.20%)
NVDA   463.52 (+1.85%)
NIO   7.46 (+1.91%)
BABA   72.63 (-0.55%)
AMD   118.21 (-0.30%)
T   17.22 (+3.36%)
F   10.61 (-0.84%)
MU   73.70 (-0.79%)
CGC   0.66 (-12.31%)
GE   120.15 (-1.14%)
DIS   90.65 (-1.48%)
AMC   7.04 (-6.01%)
PFE   29.17 (-0.38%)
PYPL   57.65 (-3.68%)
XOM   100.63 (-1.76%)
S&P 500   4,564.41 (-0.12%)
DOW   36,107.39 (-0.27%)
QQQ   386.78 (+0.12%)
AAPL   193.04 (+1.91%)
MSFT   371.97 (+0.77%)
META   318.28 (-0.54%)
GOOGL   130.87 (+1.24%)
AMZN   146.86 (+1.39%)
TSLA   238.40 (+1.20%)
NVDA   463.52 (+1.85%)
NIO   7.46 (+1.91%)
BABA   72.63 (-0.55%)
AMD   118.21 (-0.30%)
T   17.22 (+3.36%)
F   10.61 (-0.84%)
MU   73.70 (-0.79%)
CGC   0.66 (-12.31%)
GE   120.15 (-1.14%)
DIS   90.65 (-1.48%)
AMC   7.04 (-6.01%)
PFE   29.17 (-0.38%)
PYPL   57.65 (-3.68%)
XOM   100.63 (-1.76%)

Evaxion Biotech A/S Stock Price, News & Analysis (NASDAQ:EVAX)

$0.61
-0.21 (-25.60%)
(As of 03:46 PM ET)
Compare
Today's Range
$0.55
$0.77
50-Day Range
$0.68
$1.17
52-Week Range
$0.47
$2.44
Volume
751,997 shs
Average Volume
275,072 shs
Market Capitalization
$17.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Evaxion Biotech A/S MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,172.7% Upside
$7.00 Price Target
Short Interest
Healthy
0.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Evaxion Biotech A/S in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

299th out of 949 stocks

Biological Products, Except Diagnostic Industry

48th out of 150 stocks


EVAX stock logo

About Evaxion Biotech A/S Stock (NASDAQ:EVAX)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

EVAX Stock Price History

EVAX Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
ADRs End Lower; Evaxion Biotech A/S Declines 30%
ADRs Hold Steady; Fresh2 Group Climbs 23%
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Q2 2023 Evaxion Biotech A/S Earnings Call
See More Headlines
Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/22/2023
Today
12/05/2023
Next Earnings (Estimated)
12/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVAX
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+902.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.35 per share

Miscellaneous

Free Float
16,294,000
Market Cap
$19.50 million
Optionable
Not Optionable
Beta
0.08
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Niels Iversen Moller M.D. (Age 44)
    Co-Founder, VP of Business & Director
    Comp: $120k
  • Mr. Andreas Holm Mattsson (Age 47)
    Co-Founder and Chief AI & Culture Officer
    Comp: $319k
  • Mr. Jesper Nyegaard Nissen (Age 53)
    CFO & COO
    Comp: $346.97k
  • Dr. Birgitte Rono Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $336k
  • Mr. Christian Kanstrup (Age 51)
    Chief Executive Officer
  • Dr. Jürgen Langhärig EMBA
    Ph.D., Head of Business Development & Member of Advisory Board














EVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVAX shares.
View EVAX analyst ratings
or view top-rated stocks.

What is Evaxion Biotech A/S's stock price target for 2024?

1 Wall Street research analysts have issued 1-year price targets for Evaxion Biotech A/S's shares. Their EVAX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,172.7% from the stock's current price.
View analysts price targets for EVAX
or view top-rated stocks among Wall Street analysts.

How have EVAX shares performed in 2023?

Evaxion Biotech A/S's stock was trading at $1.7750 on January 1st, 2023. Since then, EVAX shares have decreased by 69.0% and is now trading at $0.55.
View the best growth stocks for 2023 here
.

Are investors shorting Evaxion Biotech A/S?

Evaxion Biotech A/S saw a decrease in short interest in November. As of November 15th, there was short interest totaling 217,400 shares, a decrease of 22.8% from the October 31st total of 281,600 shares. Based on an average trading volume of 140,900 shares, the days-to-cover ratio is presently 1.5 days.
View Evaxion Biotech A/S's Short Interest
.

When is Evaxion Biotech A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 11th 2023.
View our EVAX earnings forecast
.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01.

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are Evaxion Biotech A/S's major shareholders?

Evaxion Biotech A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include AE Wealth Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EVAX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -